COMMUNIQUÉS West-GlobeNewswire
-
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
15/06/2026 -
France Biotech to Showcase the Strength and Global Momentum of French HealthTech at BIO International Convention 2026 in San Diego
15/06/2026 -
Medicana Health Group Celebrates Two Major Recognitions in Capital Magazine’s CSR Research
15/06/2026 -
Cardiawave Announces First Routine Treatments Performed with Valvosoft® Following CE Mark Approval and Accelerates Its Deployment
15/06/2026 -
Wildfire Smoke Reaches Record Levels as Americans Struggle to Breathe
15/06/2026 -
BioSyent to Present at Planet MicroCap Las Vegas
15/06/2026 -
SafeSpace Global Appoints Michael Hrynuik as Chief Financial Officer
15/06/2026 -
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
15/06/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
15/06/2026 -
Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
15/06/2026 -
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
15/06/2026 -
Applied Biologics Reports Statistically Significant Improvement in Wound Closure Outcomes in Updated Analyses of the CAMPX Randomized Controlled Trial Evaluating XWRAP®
15/06/2026 -
Sienna Announces June Dividend
15/06/2026 -
KFSH Highlights Provider Transformation Through Measurable Operational Impact at HLTH Europe 2026
15/06/2026 -
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
15/06/2026 -
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
15/06/2026 -
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
15/06/2026 -
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
15/06/2026 -
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
15/06/2026
Pages